TGR-1202 + Ruxolitinib in Subjects With Myelofibrosis, MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea

Trial Profile

TGR-1202 + Ruxolitinib in Subjects With Myelofibrosis, MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Ruxolitinib (Primary) ; Umbralisib (Primary)
  • Indications Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Dec 2016 Results of preliminary analysis (n=11) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Results (n=12) published in a TG Therapeutics media release.
    • 03 Nov 2016 According to a TG Therapeutics media release, preliminary data from the study will be presented at the upcoming 58th American Society of Hematology (ASH) annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top